PMA device
Hydrus Microstent
Alcon Research, LLC · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Aug 10, 2018, newest Jan 30, 2025Glaucoma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
14
Naming "Hydrus Microstent"
MAUDE reports
405
Brand "Hydrus Microstent", since 2015
PubMed studies
107
Mentioning "Hydrus Microstent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hydrus Microstent
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Hydrus MicrostentPMA supplement
P170034-S013 · Decided Jan 30, 2025 · 112 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- Hydrus® MicrostentPMA supplement
P170034-S011 · Decided Aug 28, 2024 · 364 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- Hydrus MicrostentPMA supplement
P170034-S004 · Decided Jan 23, 2020 · 57 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
3 more FDA decisions with a free account
Older decisions: P170034
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Hydrus Microstent", any status and sponsor, newest update first.
Alcon ResearchNot on our public-company list
NCT04553523 · 545 participants (planned) · Start Aug 25, 2020 · Primary completion Oct 2028
Device: Hydrus Microstent; Monofocal IOL · For: Primary Open Angle Glaucoma
Sites: Irvine, California; Sacramento, California; Loveland, Colorado · 22 sites in all
Aquea Health, Inc.Not on our public-company list
NCT07836855 · 16 participants · Start Sep 16, 2024 · Primary completion Jun 15, 2026
Device: Aquea Zealix™; Hydrus® Microstent · For: Cataract Senile; Glaucoma, Open Angle
Sites: Santa Rosa de Copán, Honduras
Ivantis, Inc.Not on our public-company list
NCT03267134 · 217 participants · Start Aug 1, 2017 · Primary completion Dec 16, 2022
Device: Hydrus Microstent · For: Open-angle Glaucoma
Sites: Fayetteville, Arkansas; Sacramento, California; Fort Collins, Colorado · 20 sites in all
11 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hydrus Microstent", and for the whole product code for context.
This brand
405 reports: 104 malfunction, 301 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
- HYDRUS MICROSTENTMalfunction
Ivantis, Inc. (subsidiary of Alcon Research, LLC)
3016075957-2026-00107 · Received Oct 26, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Difficult to Advance
Patient problem as coded: Insufficient Information
- HYDRUS MICROSTENTMalfunction
Ivantis, Inc. (subsidiary of Alcon Research, LLC)
3016075957-2026-00106 · Received Oct 26, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Difficult to Advance
Patient problem as coded: Insufficient Information
- HYDRUS MICROSTENTMalfunction
Ivantis, Inc. (subsidiary of Alcon Research, LLC)
3016075957-2026-00105 · Received Oct 26, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Difficult to Advance
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hydrus Microstent"[tiab]. The summary above synthesizes these.
- Minimally Invasive Glaucoma Surgery: A Review of the Literature.
Balas M, Mathew DJ · Vision (Basel) · 2023Review
- Hydrus Microstent malposition with uveitis-glaucoma-hyphema syndrome.
Capitena Young CE, St Peter DM, Ertel MK, et al. · Am J Ophthalmol Case Rep · 2022
- Hydrus microstent for the treatment of primary open-angle glaucoma: overview of its safety and efficacy.
Fea AM, Ricardi F, Cariola R, et al. · Expert Rev Med Devices · 2023Review
- A mysterious myopic surprise.
Fram NR, Bedrood S, Durr GM, et al. · J Cataract Refract Surg · 2022Case Reports
- Complications of micro-invasive glaucoma surgery.
Yook E, Vinod K, Panarelli JF · Curr Opin Ophthalmol · 2018Review
- Combined Phacoemulsification and Hydrus Microstent Implantation in Asian Eyes With Moderate-to-Severe Normal Tension Glaucoma-12-Month Outcomes.
Ang BCH, Chen EJ, Chee WK, et al. · J Glaucoma · 2024
- Ab interno Schlemm's Canal Surgery.
Francis BA, Akil H, Bert BB · Dev Ophthalmol · 2017Review
- Removal of Hydrus® microstent due to uveitis-glaucoma-hyphema syndrome.
Hong Z, Joiner DW, Atik A · J Fr Ophtalmol · 2023
- Short-Term Outcomes of Hydrus Microstent With and Without Additional Canaloplasty During Cataract Surgery.
Dickinson A, Leidy L, Nusair O, et al. · J Glaucoma · 2023
- Spotlight on Schlemm's Canal MicroStent Injection in Patients with Glaucoma.
Wagner IV, Ang B, Checo L, et al. · Clin Ophthalmol · 2023Review
- Five-Year Visual Field Outcomes of the HORIZON Trial.
Montesano G, Ometto G, Ahmed IIK, et al. · Am J Ophthalmol · 2023Randomized Controlled Trial, Multicenter Study
- Hydrus microstent implantation for surgical management of glaucoma: a review of design, efficacy and safety.
Samet S, Ong JA, Ahmed IIK · Eye Vis (Lond) · 2019Review
Other devices of this type
Also filed under product code OGO.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiGlaukos Corporation · PMA 2022
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- CyPass System 241-SAlcon Research, Ltd. · PMA 2018
- Glaukos Trabecular Micro Bypass Stent Model GTS100R/LGlaukos Corporation · PMA 2013
- CyPass Micro-StentAlcon Research, Ltd. · PMA 2020
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
- Hydrus MicrosentAlcon Research, LLC · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.